FinscoFinsco

Celldex Therapeutics (US.CLDX)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CLDX · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion102.5%→
ROE-17.2%↓
Cash Conversion-→
D/E Ratio0.00↑
Gross Margin0.0%↓
US.CLDX (Celldex Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   102.5%    →
ROE              -17.2%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↑
Gross Margin       0.0%    ↓
Key Metrics
US.CLDX (Celldex Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 102.5% →
ROE -17.2% ↓
Cash Conversion - →
D/E Ratio 0.00 ↑
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies